CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade RxSight, Inc. - RXST CFD

    27.17
    0.69%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.11
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Rxsight Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 27.36
    Open* 27.47
    1-Year Change* 135.59%
    Day's Range* 27.1 - 28.07
    52 wk Range 9.78-33.77
    Average Volume (10 days) 436.66K
    Average Volume (3 months) 10.02M
    Market Cap 1.06B
    P/E Ratio -100.00K
    Shares Outstanding 35.64M
    Revenue 67.00M
    EPS -1.94
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Nov 6, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 22, 2023 27.17 0.20 0.74% 26.97 28.19 26.76
    Sep 21, 2023 27.36 -0.35 -1.26% 27.71 27.75 26.46
    Sep 20, 2023 28.30 0.15 0.53% 28.15 28.76 27.71
    Sep 19, 2023 28.33 0.77 2.79% 27.56 28.77 27.48
    Sep 18, 2023 28.19 -1.53 -5.15% 29.72 29.79 28.12
    Sep 15, 2023 29.77 0.01 0.03% 29.76 29.88 29.44
    Sep 14, 2023 29.62 0.06 0.20% 29.56 29.64 28.77
    Sep 13, 2023 29.55 2.14 7.81% 27.41 29.84 27.22
    Sep 12, 2023 27.64 -1.82 -6.18% 29.46 29.86 27.54
    Sep 11, 2023 30.12 1.08 3.72% 29.04 30.39 28.82
    Sep 8, 2023 28.94 -0.63 -2.13% 29.57 30.60 28.77
    Sep 7, 2023 29.65 0.27 0.92% 29.38 30.46 28.96
    Sep 6, 2023 29.45 1.23 4.36% 28.22 29.48 28.22
    Sep 5, 2023 28.43 -0.54 -1.86% 28.97 28.97 28.18
    Sep 1, 2023 29.12 0.66 2.32% 28.46 29.45 28.46
    Aug 31, 2023 28.93 0.94 3.36% 27.99 29.23 27.99
    Aug 30, 2023 29.00 1.02 3.65% 27.98 29.18 27.98
    Aug 29, 2023 28.61 0.61 2.18% 28.00 28.88 27.57
    Aug 28, 2023 28.18 -1.28 -4.34% 29.46 29.79 28.08
    Aug 25, 2023 29.45 0.26 0.89% 29.19 29.76 28.99

    RxSight, Inc. Events

    Time (UTC) Country Event
    Monday, November 6, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 Rxsight Inc Earnings Release
    Q3 2023 Rxsight Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, March 4, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Rxsight Inc Earnings Release
    Q4 2023 Rxsight Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Total revenue 49.005 22.593 14.678 2.241
    Revenue 49.005 22.593 14.678 2.241
    Cost of Revenue, Total 27.677 18.076 12.973 4.06
    Gross Profit 21.328 4.517 1.705 -1.819
    Total Operating Expense 112.323 75.38 50.09 48.311
    Selling/General/Admin. Expenses, Total 58.961 33.077 15.132 15.178
    Research & Development 25.657 24.202 21.819 29.42
    Depreciation / Amortization 0.028 0.025 0.159 0.174
    Unusual Expense (Income) 0 0.007 -0.521
    Operating Income -63.318 -52.787 -35.412 -46.07
    Interest Income (Expense), Net Non-Operating -3.429 -3.628 0.033 2.281
    Other, Net 0 7.735 63.011 170.033
    Net Income Before Taxes -66.747 -48.68 27.632 126.244
    Net Income After Taxes -66.756 -48.688 27.575 126.22
    Net Income Before Extra. Items -66.756 -48.688 27.575 126.22
    Net Income -66.756 -48.688 27.575 126.22
    Total Adjustments to Net Income 0 -24.209 -100.093
    Income Available to Common Excl. Extra. Items -66.756 -48.688 3.366 26.127
    Income Available to Common Incl. Extra. Items -66.756 -48.688 3.366 26.127
    Diluted Net Income -66.756 -48.688 3.366 26.127
    Diluted Weighted Average Shares 28.2684 27.3668 26.295 26.295
    Diluted EPS Excluding Extraordinary Items -2.36151 -1.77909 0.12801 0.99361
    Diluted Normalized EPS -2.36151 -1.77909 0.12827 0.9738
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 20.81 17.489 16.088 12.615 11.36
    Revenue 20.81 17.489 16.088 12.615 11.36
    Cost of Revenue, Total 8.795 7.123 8.666 7.259 6.572
    Gross Profit 12.015 10.366 7.422 5.356 4.788
    Total Operating Expense 34.797 30.586 31.078 28.573 27.152
    Selling/General/Admin. Expenses, Total 18.254 16.283 15.803 15 14.469
    Research & Development 7.348 7.137 6.599 6.275 6.075
    Depreciation / Amortization 0.038 0.043 0.01 0.039 0.036
    Operating Income -13.987 -13.097 -14.99 -15.958 -15.792
    Interest Income (Expense), Net Non-Operating 0.209 -0.115 -0.615 -0.86 -0.94
    Other, Net 0 0 0
    Net Income Before Taxes -13.778 -13.212 -15.605 -16.818 -16.732
    Net Income After Taxes -13.804 -13.212 -15.61 -16.818 -16.732
    Net Income Before Extra. Items -13.804 -13.212 -15.61 -16.818 -16.732
    Net Income -13.804 -13.212 -15.61 -16.818 -16.732
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -13.804 -13.212 -15.61 -16.818 -16.732
    Income Available to Common Incl. Extra. Items -13.804 -13.212 -15.61 -16.818 -16.732
    Diluted Net Income -13.804 -13.212 -15.61 -16.818 -16.732
    Diluted Weighted Average Shares 34.4983 31.6371 30.4196 27.6658 27.5599
    Diluted EPS Excluding Extraordinary Items -0.40014 -0.41761 -0.51316 -0.6079 -0.60711
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.39332 -0.41761 -0.51316 -0.6079 -0.60711
    Unusual Expense (Income) 0.362
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Total Current Assets 134.555 176.295 81.5 90.199
    Cash and Short Term Investments 105.802 159.332 68.975 80.668
    Cash & Equivalents 11.834 24.361 13.994 7.958
    Short Term Investments 93.968 134.971 54.981 72.71
    Total Receivables, Net 10.956 4.862 2.865 0.789
    Accounts Receivable - Trade, Net 10.956 4.862 2.865 0.789
    Total Inventory 14.835 8.032 8.288 7.219
    Prepaid Expenses 2.962 4.069 1.372 1.523
    Total Assets 150.164 192.721 100.677 110.432
    Property/Plant/Equipment, Total - Net 14.081 15.501 18.606 19.25
    Property/Plant/Equipment, Total - Gross 33.979 31.846 30.979 27.789
    Accumulated Depreciation, Total -19.898 -16.345 -12.373 -8.539
    Other Long Term Assets, Total 1.528 0.925 0.571 0.983
    Total Current Liabilities 17.237 11.077 11.6 8.457
    Accounts Payable 2.595 1.689 1.134 2.199
    Accrued Expenses 10.81 8.615 4.935 5.715
    Notes Payable/Short Term Debt 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.152 0.02 0.027 0.129
    Other Current Liabilities, Total 3.68 0.753 5.504 0.414
    Total Liabilities 60.262 54.479 44.906 87.462
    Total Long Term Debt 40.212 39.777 24.436 0.054
    Long Term Debt 40.169 39.76 24.399 0
    Capital Lease Obligations 0.043 0.017 0.037 0.054
    Other Liabilities, Total 2.813 3.625 8.87 78.951
    Total Equity 89.902 138.242 55.771 22.97
    Redeemable Preferred Stock 0 353.3 327.581
    Common Stock 0.028 0.027 80.78 56.422
    Retained Earnings (Accumulated Deficit) -546.032 -479.276 -377.503 -360.224
    Other Equity, Total -0.095 -0.02 -0.806 -0.809
    Total Liabilities & Shareholders’ Equity 150.164 192.721 100.677 110.432
    Total Common Shares Outstanding 28.2684 27.3668 26.295 26.295
    Additional Paid-In Capital 636.001 617.511
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 187.666 134.555 139.162 149.928 161.147
    Cash and Short Term Investments 153.939 105.802 112.835 128.62 143.847
    Cash & Equivalents 11.012 11.834 8.912 24.004 24.132
    Short Term Investments 142.927 93.968 103.923 104.616 119.715
    Total Receivables, Net 12.668 10.956 9.02 6.884 5.626
    Accounts Receivable - Trade, Net 12.668 10.956 9.02 6.884 5.626
    Total Inventory 18.067 14.835 15.336 11.622 8.49
    Prepaid Expenses 2.992 2.962 1.971 2.802 3.184
    Total Assets 202.532 150.164 155.706 166.714 177.062
    Property/Plant/Equipment, Total - Net 13.359 14.081 14.951 15.787 14.972
    Other Long Term Assets, Total 1.507 1.528 1.593 0.999 0.943
    Total Current Liabilities 14.876 17.237 16.368 12.996 10.659
    Accounts Payable 3.717 2.595 4.172 3.277 2.587
    Accrued Expenses 11.045 14.49 12.036 9.593 7.997
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.114 0.152 0.16 0.126 0.075
    Other Current Liabilities, Total
    Total Liabilities 57.523 60.262 59.747 56.728 53.899
    Total Long Term Debt 40.309 40.212 40.099 39.988 39.974
    Long Term Debt 40.309 40.169 40.025 39.881 39.89
    Capital Lease Obligations 0 0.043 0.074 0.107 0.084
    Other Liabilities, Total 2.338 2.813 3.28 3.744 3.266
    Total Equity 145.009 89.902 95.959 109.986 123.163
    Redeemable Preferred Stock
    Common Stock 0.034 0.028 0.028 0.027 0.027
    Additional Paid-In Capital 704.228 636.001 626.491 623.746 620.106
    Retained Earnings (Accumulated Deficit) -559.244 -546.032 -530.422 -513.604 -496.872
    Other Equity, Total -0.009 -0.095 -0.138 -0.183 -0.098
    Total Liabilities & Shareholders’ Equity 202.532 150.164 155.706 166.714 177.062
    Total Common Shares Outstanding 33.9667 28.2684 27.7191 27.6315 27.4857
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Net income/Starting Line -66.756 -48.688 27.575 126.22
    Cash From Operating Activities -58.85 -44.708 -35.203 -40.619
    Cash From Operating Activities 4.022 3.988 4.012 3.93
    Non-Cash Items 11.296 2.67 -58.942 -166.798
    Cash Taxes Paid 0.003 0.02 0.061 0.019
    Cash Interest Paid 4.257 3.187 0.425 0.026
    Changes in Working Capital -7.412 -2.678 -7.848 -3.971
    Cash From Investing Activities 39.95 -81.907 15.591 -5.87
    Capital Expenditures -2.393 -1.94 -2.539 -4.086
    Other Investing Cash Flow Items, Total 42.343 -79.967 18.13 -1.784
    Cash From Financing Activities 6.332 137.342 25.237 1.33
    Financing Cash Flow Items -1.375 -0.132 -0.687 0
    Issuance (Retirement) of Stock, Net 7.828 122.501 1.066 1.515
    Issuance (Retirement) of Debt, Net -0.121 14.973 24.858 -0.185
    Foreign Exchange Effects -0.009 -0.01 0.005
    Net Change in Cash -12.577 10.717 5.625 -45.154
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -13.212 -66.756 -51.146 -34.328 -17.596
    Cash From Operating Activities -17.764 -58.85 -44.996 -29.808 -14.985
    Cash From Operating Activities 0.999 4.022 3.061 2.081 1.035
    Non-Cash Items 2.189 11.296 8.675 5.707 2.805
    Cash Taxes Paid 0 0.003 0.003 0.003 0
    Cash Interest Paid 1.348 4.257 3.037 1.907 0.928
    Changes in Working Capital -7.74 -7.412 -5.586 -3.268 -1.229
    Cash From Investing Activities -48.365 39.95 29.545 28.985 14.859
    Capital Expenditures -0.747 -2.393 -2.031 -1.451 -0.37
    Other Investing Cash Flow Items, Total -47.618 42.343 31.576 30.436 15.229
    Cash From Financing Activities 65.305 6.332 0.025 0.48 -0.098
    Financing Cash Flow Items -0.567 -1.375 -1.082 -0.504 -0.362
    Issuance (Retirement) of Stock, Net 65.913 7.828 1.189 1.044 0.308
    Issuance (Retirement) of Debt, Net -0.041 -0.121 -0.082 -0.06 -0.044
    Foreign Exchange Effects 0.002 -0.009 -0.023 -0.014 -0.005
    Net Change in Cash -0.822 -12.577 -15.449 -0.357 -0.229

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    RxSight, Inc. Company profile

    About Rxsight Inc

    RxSight, Inc. is a commercial-stage medical technology company. The Company is engaged in improving the vision of patients following cataract surgery. Its RxSight Light Adjustable Lens system (RxSight system), comprised of its RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. Its LAL is made of photosensitive material that changes shape in response to patterns of ultraviolet (UV) light generated by its LDD. Its RxSight system helps surgeon to performs a standard cataract procedure to implant the LAL, and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes. Alternative IOL technologies, are not adjustable following the surgery and therefore require patients to make pre-operative choices about their visual preferences.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Rxsight Inc revenues increased 54% to $22.6M. Net loss applicable to common stockholders totaled $48.7M vs. income of $3.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Change in fair value of warrants decrease of 96% to $2.7M (income), Selling, general and administrative - B increase from $15.1M to $31.2M

    Industry: Medical Equipment, Supplies & Distribution (NEC)

    100 Columbia Street
    Suite 120
    ALISO VIEJO
    CALIFORNIA 92656
    US

    Income Statement

    • Annual
    • Quarterly

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    US100

    14,710.90 Price
    +0.190% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    BTC/USD

    26,621.60 Price
    -0.060% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    XRP/USD

    0.51 Price
    +0.040% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Oil - Crude

    90.14 Price
    +0.770% 1D Chg, %
    Long position overnight fee 0.0415%
    Short position overnight fee -0.0634%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading